Back

Assessment of absolute reductions in LDL-C associated with alirocumab therapy: results from across the Phase 3 ODYSSEY programme

27 August 2017 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 2 - Lipids Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Eli Roth

University of Cincinnati, Cincinnati (United States of America)

14 More presentations in this session

Presentation thumbnail
Professor B. Cariou (Nantes, FR)
Abstract
Presentation thumbnail
Doctor L. Pedersen (Copenhagen, DK)
Abstract
Presentation thumbnail
Doctor J. Meeusen (Rochester, US)
Abstract
Presentation thumbnail
Doctor E. Zomer (Victoria, AU)
Abstract
Presentation thumbnail
Associate Professor R. Santos (Sao Paulo, BR)
Abstract

Access the full session

Session thumbnail
Poster session 2 - Lipids

The Event

Event poster

ESC Congress 2017

27 August 2017 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment
2 September 2019
thumbnail
Webinar
How to treat patients with borderline dyslipidemia
8 February 2023
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in reducing LDL cholesterol and triglycerides: real-life experience in a third level hospital: a descriptive, bivariate, and multivariate analysis.
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources